Biogen to Present 96-Week Data From Diranersen Alzheimer’s Trial at CTAD 2026

Bitget2026/10/29 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Biogen will present new Alzheimer’s disease study data at CTAD in Boston, November 16-19, 2026.
Investigational diranersen’s Phase 2 CELIA update will cover longer-term efficacy, safety and biomarkers, building on results presented in July 2026.
Leqembi presentations will examine five-year treatment outcomes and safety, alongside three-year real-world evidence on maintenance therapy and at-home subcutaneous administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290659PRIMZONEFULLFEED9855736) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.

华尔街见闻•2026/11/06 23:26